Payment overview · 2025
General Payments
$90.29
5 reported records · 2 companies
Healthcare provider profile · identity verified
Michael L. Ard, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LOUISVILLE, MS · NPI 1962484899
Verified facts
What the public records show
CMS Open Payments records show Michael L. Ard, M.D. received $90.29 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 81.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.39 | 81.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.90 | 18.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.29 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.41 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 573 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 561 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 482 | 67 |
| Lisinopril | Lisinopril | 327 | 64 |
| Gabapentin | Gabapentin | 312 | 56 |
| Potassium Chloride | Potassium Chloride | 303 | 55 |
| Losartan Potassium | Losartan Potassium | 295 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 53 |
| Donepezil Hcl | Donepezil Hcl | 291 | 41 |
| Omeprazole | Omeprazole | 273 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 52 |
| Furosemide | Furosemide | 225 | 40 |
| Eliquis | Apixaban | 209 | 17 |
| Montelukast Sodium | Montelukast Sodium | 198 | 27 |
| Metformin Hcl | Metformin Hcl | 187 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 30 |
| Trazodone Hcl | Trazodone Hcl | 166 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 38 |
| Clonazepam | Clonazepam | 146 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 143 | 15 |
| Allopurinol | Allopurinol | 135 | 28 |
| Famotidine | Famotidine | 132 | 21 |
| Meloxicam | Meloxicam | 132 | 29 |
| Sertraline Hcl | Sertraline Hcl | 131 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 17 |
| Ozempic | Semaglutide | 113 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | suppressed |
| Carvedilol | Carvedilol | 104 | 25 |
| Memantine Hcl | Memantine Hcl | 102 | 15 |
| Tramadol Hcl | Tramadol Hcl | 102 | 25 |
| Ezetimibe | Ezetimibe | 98 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 17 |
| Prednisone | Prednisone | 91 | 47 |
| Simvastatin | Simvastatin | 85 | 12 |
| Mirtazapine | Mirtazapine | 81 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 14 |
| Spironolactone | Spironolactone | 77 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | suppressed |
| Synthroid | Levothyroxine Sodium | 69 | suppressed |
| Sucralfate | Sucralfate | 62 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 12 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 23 |
| Baclofen | Baclofen | 45 | suppressed |
| Colchicine | Colchicine | 43 | 15 |
| Finasteride | Finasteride | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 15 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Olanzapine | Olanzapine | 35 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Ondansetron Odt | Ondansetron | 30 | 23 |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Digoxin | Digoxin | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 17 |
| Haloperidol | Haloperidol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Novolin R | Insulin Regular, Human | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Austedo | Deutetrabenazine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Daptomycin | Daptomycin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.29 · 5 records | AstraZeneca Pharmaceuticals LP | BREZTRI, FARXIGA, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error